Cargando…
Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains cha...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971810/ https://www.ncbi.nlm.nih.gov/pubmed/36865792 http://dx.doi.org/10.3389/fonc.2023.1023787 |
_version_ | 1784898180784062464 |
---|---|
author | Qin, Ruoyan Qian, Jie Shan, Mengjun Ruan, Guangxin Yang, Xiaofeng Wang, Yanwen Liu, Lingshuang |
author_facet | Qin, Ruoyan Qian, Jie Shan, Mengjun Ruan, Guangxin Yang, Xiaofeng Wang, Yanwen Liu, Lingshuang |
author_sort | Qin, Ruoyan |
collection | PubMed |
description | Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains challenging. Breast cancer is highly heterogeneous, and the expression of hormone receptors is often inconsistent between primary and metastatic lesions. Here, we report a case of triple-negative breast cancer 17 years after surgery with lung metastases for 5 years that progressed to pleural metastases after multiple lines of chemotherapy. The pleural pathology suggested ER (+) and PR (+) and transformation to luminal A breast cancer. This patient received fifth-line letrozole endocrine therapy and achieved partial response (PR). The patient’s cough and chest tightness improved after treatment, associated tumor markers decreased, and progression-free survival (PFS) exceeded 10 months. Our results may be of clinical relevance for patients with hormone receptor alterations in advanced triple-negative breast cancer and suggest that individualized regimens should be developed for breast cancer based on the molecular expression of tumor tissue at the primary and metastatic sites. |
format | Online Article Text |
id | pubmed-9971810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99718102023-03-01 Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors Qin, Ruoyan Qian, Jie Shan, Mengjun Ruan, Guangxin Yang, Xiaofeng Wang, Yanwen Liu, Lingshuang Front Oncol Oncology Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains challenging. Breast cancer is highly heterogeneous, and the expression of hormone receptors is often inconsistent between primary and metastatic lesions. Here, we report a case of triple-negative breast cancer 17 years after surgery with lung metastases for 5 years that progressed to pleural metastases after multiple lines of chemotherapy. The pleural pathology suggested ER (+) and PR (+) and transformation to luminal A breast cancer. This patient received fifth-line letrozole endocrine therapy and achieved partial response (PR). The patient’s cough and chest tightness improved after treatment, associated tumor markers decreased, and progression-free survival (PFS) exceeded 10 months. Our results may be of clinical relevance for patients with hormone receptor alterations in advanced triple-negative breast cancer and suggest that individualized regimens should be developed for breast cancer based on the molecular expression of tumor tissue at the primary and metastatic sites. Frontiers Media S.A. 2023-02-14 /pmc/articles/PMC9971810/ /pubmed/36865792 http://dx.doi.org/10.3389/fonc.2023.1023787 Text en Copyright © 2023 Qin, Qian, Shan, Ruan, Yang, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qin, Ruoyan Qian, Jie Shan, Mengjun Ruan, Guangxin Yang, Xiaofeng Wang, Yanwen Liu, Lingshuang Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
title | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
title_full | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
title_fullStr | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
title_full_unstemmed | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
title_short | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
title_sort | case report: response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971810/ https://www.ncbi.nlm.nih.gov/pubmed/36865792 http://dx.doi.org/10.3389/fonc.2023.1023787 |
work_keys_str_mv | AT qinruoyan casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT qianjie casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT shanmengjun casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT ruanguangxin casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT yangxiaofeng casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT wangyanwen casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors AT liulingshuang casereportresponsetoendocrinetherapyintriplenegativebreastcancermetastaseswithalteredhormonereceptors |